Multikinase inhibitors: Multikinase inhibitors: Regorafenib skin toxicity. Cutaneous side effects of multikinase-inhibitors and their management
|
|
- Marian Elliott
- 6 years ago
- Views:
Transcription
1 TARGETED THERAPIES AND THEIR CUTANEOUS TOXICITIES Brussels, 14/1/2017 Cutaneous side effects of multikinase-inhibitors and their management Siegfried Segaert Dermatology Dept. Uinversity Hospital Leuven 4 th BADO meeting Brussels, January 14 th 2017 Multikinase inhibitors: - Regorafenib (Stivarga ; VEGFR1-3, (B)RAF, PDGFRβ, c-kit) - Sorafenib (Nexavar ; RAF, VEGFR2-3, PDGFRβ, FLT3) - Sunitinib (Sutent ; c-kit, VEGFR2, PDGFRβ, FLT3) - Imatinib (Gleevec, c-kit, BCR-ABL, PDGFRβ) - Axitinib, linifanib, pazopanib Multikinase inhibitors: - Sorafenib (Nexavar ) - Sunitinib (Sutent ) - Imatinib (Gleevec ) - Regorafenib (Stivarga ) Regorafenib: AEs in previously-treated mcrc The most common ( 10%) drug-related, treatment-emergent AEs of any grade experienced by patients enrolled in CORRECT 1 Regorafenib skin toxicity Regorafenib + BSC (n=500) Placebo + BSC (n=253) Treatment-related adverse event, % All grades Grade 3 Grade All 4 grades Grade Grade 3 4 Hand foot skin 47% 17% 0 8% <1% 0 reaction Fatigue 47% 9% <1% 28% 5% <1% Diarrhea 34% 7% <1% 8% 1% 0 Anorexia 30% 3% 0 15% 3% 0 Voice changes 29% <1% 0 6% 0 0 Hypertension 28% 7% 0 6% 1% 0 Oral mucositis 27% 3% 0 4% 0 0 Rash or desquamation 26% 6% 0 4% 0 0 Nausea 14% <1% 0 11% 0 0 Weight loss 14% 0 0 2% 0 0 Thrombocytopenia 13% 3% <1% 2% <1% 0 Fever 10% 1% 0 3% 0 0 Grothey A, et al. Lancet. 2013;381:
2 Hand-Foot Skin Reaction (HFSR) HFSR over time HFSR is distinct from the more widely known hand foot syndrome (HFS also known as PPE, palmar-plantar erythrodysesthesia) which occurs with older therapies such as capecitabine 1 Cutaneous areas typically affected by HFSR are those under the most pressure or friction, such as the palms of the hand, soles of the feet, fingers or toes 1,2 HFSR typically develops soon (2 4 weeks) after a patient starts treatment 2 HFSR is not life-threatening and usually resolves with appropriate management and/or dose modification 2 Frequency of HFSR (%) # Patients at risk Treatment Cycle CORRECT (n=500) Grade 1 Grade 3 1. Wood LS, et al. Commun Oncol. 2010;7: Lacouture ME, et al. Oncologist. 2008;13: AE, adverse events; CORRECT, COloRectal cancer treated with REgorafenib or Grothey A, et al. ASCO GI, Abstract 467. placebo after failure of standard Therapy; mcrc, metastatic colorectal cancer. HFSR: clinical presentation Grade 1 HFSR is characterized by lesions localized to frictional and weight bearing areas of the skin (heels, metatarsal heads, ) 1,2 Initially, affected areas become tender and erythematous 1 Lesions become edematous and evolve into painful blisters 1 Blisters transform into painful calluses (thickening of the epidermis) affecting the patient s ability to perform daily activities 1,2 Photographs courtesy of Kathleen Polson, N.P. 1. Lacouture ME, et al. Oncologist. 2008;13: Wood LS, et al. Commun Oncol 2010;7:23-9. Grade 1 2
3 Grade 3 Grade 3 3
4 HFSR: symptoms : clinical picture HFSR symptoms may include: 1,2 Tenderness Dysesthesia and paresthesia (numbness feeling of pins and needles) Pain Intolerance to contact with hot objects often precedes or accompanies HFSR 3 Hand-foot syndrome Lesions on friction/pressure points Entire palms/soles Onset after days to weeks Onset after weeks to months Painful blister callus Erythema, edema, scaling Dysesthesia, pain Dysesthesia, pain Regorafenib, sorafenib, sunitinib, 5-FU, capecitabine vemurafenib, dabrafenib, axitinib, doxorubicine, cytarabine pazopanib Insufficient repair of frictional skin trauma due to inhibition VEGFR + PDGFR Concentration of cytostatic in skin via eccrine sweat ducts 1. Wood LS, et al. Commun Oncol. 2010;7: Lacouture ME, et al. Oncologist 2008;13: Robert C, et al. J Am Acad Dermatol. 2009;60: McLellan et al. Ann Oncol 2015; 26: , : histopathology : pathophysiology Repetitive frictional trauma on thick epidermis of palms and soles Repair mechanisms fail due to inhibition of VEGFR and PDGFR Keratinocyte necrosis spongiosis (intraepidermal edema) blister formation Intensive inflammation Hyperproliferation of epidermal keratinocytes Hyperkeratosis and callus formation Faivre et al. J Clin Oncol 2006; 24: Yang et al. Br J Dermatol 2008; 158: McLellan et al. Ann Oncol 2015; 26: , 4
5 : treatment : treatment - Preventive measures: - remove calluses before starting treatment - avoid friction, pressure, irritation - nicely fitting shoes (no sandals or slippers) / cotton socks - wear gloves for washing, cleaning, working - don t wash hands too often and avoid very hot water use wash oil e.g. Eucerin wash oil - use hand- or foot cream hand cream: Neutrogena, Huizinga Fagron, Eucerin hand cream foot cream: Xerial feet, Eucerin foot cream - pressure absorbing silicone shoe sole - Ultrapotent topical steroids for inflammation (redness, blisters) e.g. Dermovate, preparation with salicylic acid + clobetasolpropionate - Urea or salicylic acid ointment for hyperkeratosis (callus) e.g. Xerial 10 (feet), Xerial 30, Xerial 50 salicylic acid in preparation by dermatologist - Topical anaesthetics for pain e.g. Xylocain gel - Oral analgetics for pain if insufficient - When the lesions are wet, take a swab and use oral antibiotics (adjust according to antibiogram) e.g. fluxloxacillin, cefuroxim HFSR management: dose modifications Maculopapular rash GRADE 1 GRADE 2 GRADE 3 First Occurrence Maintain dose level Consider decreasing dose by 1 dose level and institute Institute immediate support measures. Interrupt and institute immediate immediate supportive measures. therapy for a minimum of 7 days until toxicity supportive measures If no improvement, interrupt therapy for a minimum of 7 resolves to Grade 0-1. for symptomatic relief days, until toxicity resolves to grade 0 1. When resuming treatment, decrease dose by 1 A dose reescalation is permitted at the discretion of the dose level. A dose reescalation is permitted at treating physician the discretion of the treating physician Second Occurrence *Interrupt therapy until toxicity resolves to Grade 0-1. Institute immediate supportive measures. When resuming treatment, treat at reduced dose level. Interrupt therapy for a minimum of 7 days until A dose reescalation is permitted at the discretion of the toxicity resolves to grade 0 1. When resuming treating physician treatment, decrease dose by 1 additional dose level Third Occurrence Skin rash may occur in patients treated with kinase inhibitors, including regorafenib 26% of patients enrolled in CORRECT who were treated with regorafenib experienced skin rash or desquamation (all grades), compared with 4% of patients treated with placebo 1 Symptoms associated with skin rash may include: 2-4 Erythematous macules or papules, suddenly appearing in a symmetrical way Itch Rarely pain, blisters, mucosal involvement in severe cases Interrupt therapy until toxicity resolves to Grade 0-1. When resuming treatment, treat at reduced dose level (minimum 80 mg daily). A dose reescalation is permitted at the discretion of the treating physician Discontinue treatment permanently Fourth Occurrence Discontinue therapy permanently Lacouture ME, et al. Oncologist. 2008;13: Grothey A, et al. Lancet. 2013;381(9863): Porta C. Clin Exp Med. 2007;7: Bellmunt J, et al. Crit Rev Onc. 2010;78: Wood LS. Commun Oncol. 2006;3: Rash over time Grade 1 Grade 3 Grade 4 Frequency of AE (%) RASH Treatment Cycle n Grothey A, et al. ASCO GI Abstract
6 -3-3 Grade 3 Grade 3 6
7 Maculopapular rash Stomatitis Oral antihistamine for itch e.g. loratadine daytime, hydroxyzine evening Anti-itch cream e.g. menthol cream Potent topical steroid for moderate to severe rashes e.g. clobetasolpropionate cream (Dermovate ) Oral steroids - Common (27%) days after start - Risk factors: old age, poor dental hygiene, poor nutritional status - Preventive measures: * dental care * mouth wash * avoid hot or spicy food - Treatment * mouthwash containing saline ± antiseptic ± antifungal ± anaesthetic Dose modification / interruption may be required for severe rash Retreatment is possible except for Stevens-Johnson syndrome, TEN or DRESS Alarm symptoms: pain, blisters, facial swelling, mucosal erosions De Wit et al. Support Care Cancer 2014; 22: Hair changes Eruptive naevi Mild alopecia Depigmentation Curly hair Sibaud et al. Eur J Dermatol 2015; 25:85-6. Sibaud et al. Eur J Dermatol 2015; 25:85-6. Regorafenib skin toxicity (50%) Alopecia (30%), depigmentation of hair, curly hair Maculopapular rash (25%) Stomatitis (25%) Seborrheic dermatitis-like rash face and scalp Eruptive naevi Keratoacanthoma Skin toxicity of other MKIs: - Sorafenib - Sunitinib - Imatinib 7
8 Sorafenib skin toxicity Sorafenib skin toxicity (35% - 70%) Seborrheic dermatitis-like rash face and scalp (65%) Maculopapular rash (20-35%) Alopecia, curly hair Stomatitis (20%) Xerosis, itch (esp. scalp), eczema Subungual splinter haemorrhages (30%) Keratosis pilaris-like follicular hyperkeratosis (20%) Inflamed seborrheic keratosis (10%) Keratinocyte neoplasia (keratosis, keratoacanthoma, SCC) (5%) Eruptive naevi (1%) Radiation recall dermatitis Sorafenib: subungual splinter haemorrhages Sorafenib: keratinocyte neoplasia Splinter haemorrhages: reflection of anti-vegfr or anti-angiogenesis effects? Robert et al. Ann Intern Med 2005; 143: Sorafenib: keratosis pilaris-like follicular hyperkeratosis Sunitinib skin toxicity Stomatitis Facial / periorbital edema Yellow discolouration of the (facial) skin Hair depigmentation Subungual splinter haemorrhages Seborrheic dermatitis-like rash face and scalp (acneiform eruption?) Xerosis, itch (esp. scalp), eczema Genital and scrotal irritation Lee et al. Br J Dermatol 2009; 161:
9 Sunitinib: hair depigmentation Sunitinib: hair depigmentation caused by inhibition c-kit (sunitinib) (anti-kit Ab) Faivre et al. J Clin Oncol 2006; 24: Moss et al. J Pharmacol Exp Ther 2003; 307: Imatinib skin toxicity Imatinib-induced edema Edema (eyelid, facial to generalized) Pigmentary changes - localized or general depigmentation (esp. dark skin) - hyperpigmentation (4%) - repigmentation of grey hair (7%) Rash (including AGEP, erythroderma, pityriasis rosea-like) Pruritus Xerosis Arora et al. Ann Oncol 2004; 15: Valeyrie et al. J Am Acad Dermatol 2003; 48: Legros et al. Br J Dermatol 2005; 153: Thank you for your kind attention! 9
Skin Side Effects U N I V E R S I T Y OF V I E N N A, D E P A R T M E N T OF O N C O L O G Y, G E N E R A L H O S P I T A L V I E N N A
Skin Side Effects Christiane Thallinger, M D U N I V E R S I T Y OF V I E N N A, D E P A R T M E N T OF O N C O L O G Y, G E N E R A L H O S P I T A L V I E N N A Targets Substances 1 Multi Kinase Inhibitors
More informationCutaneous reactions to targeted therapies. Stavonnie Patterson, MD, FAAD Northwestern University Feinberg School of Medicine March 6, 2017
Cutaneous reactions to targeted therapies Stavonnie Patterson, MD, FAAD Northwestern University Feinberg School of Medicine March 6, 2017 Disclosures I have no relevant disclosures Papulopustular Eruption
More informationEGFR inhibitors. EGFR inhibitors. Cutaneous side effects of EGFRinhibitors. EGFR inhibitor skin toxicity. EGFR is abundantly expressed in the skin
TARGETED THERAPIES AND THEIR CUTANEOUS TOXICITIES Brussels, 14/1/2017 Cutaneous side effects of EGFRinhibitors and their management Siegfried Segaert Dermatology Dept University Hospital Leuven Belgium
More information17/01/2017. Use of kinase inhibitors in oncology practice. Multikinase inhibitors. Sunitinib (Sutent )targets. Many more sunitinib kinase targets (42)
Multikinase inhibitors Use of kinase inhibitors in oncology practice Prof Jacques De Grève, UZ Brussel Inhibit multiple intracellular and cell surface kinases Tyrosine or serine-threonine kinases Multitargeting
More informationManagement of side-effects of anti-angiogenetic inhibitors in treating HCC
Management of side-effects of anti-angiogenetic inhibitors in treating HCC Massimo Di Maio Clinical Trials Unit National Cancer Institute, Napoli dimaiomax@libero.it BCLC staging system and treatment strategy
More information17/01/2017. ckit NRAS BRAF MEK ERK. ANTITUMOR IMMUNE RESPONSE PROLIFERATION
BRAF inhibitors: vemurafenib (Zelboraf ) dabrafenib (Tafinlar ) Universitair Ziekenhuis Gent MEK inhibitors: cobimetinib trametinib(mekinist ) selumetinib CUTANEOUS SIDE EFFECTS OF BRAF-INHIBITORS Lieve
More informationPei-han Kao, 高珮菡 Department of Dermatology, Chang Gang Memorial Hospital 林口長庚醫院皮膚科
Pei-han Kao, 高珮菡 Department of Dermatology, Chang Gang Memorial Hospital 林口長庚醫院皮膚科 Clear evidence that rash presence/severity correlates with response May compromise quality of life and require to minimize
More informationIdentifying and managing dermatologic toxicities associated with EGFR-inhibitor therapy. An educational resource for healthcare professionals
Identifying and managing dermatologic toxicities associated with EGFR-inhibitor therapy An educational resource for healthcare professionals What to expect from EGFR-inhibitor therapy The goal of EGFR-inhibitor
More informationManaging common toxicities with new tyrosine kinase inhibitors
Managing common toxicities with new tyrosine kinase inhibitors TKIs are involved in treating an increasing number of cancer indications. Doctors need to be aware of the range of potentially serious side
More informationDermatologists & Oncologists: Two important reasons we are getting closer. Ioanna Panoutsopoulou, MD. GAMC June 1 st 2016
Dermatologists & Oncologists: Two important reasons we are getting closer Ioanna Panoutsopoulou, MD GAMC June 1 st 2016 Points of presentation Cutaneous adverse events from: Epidermal Growth Factor Receptor
More informationThe Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma
The Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma Reinhard Dummer, 1 Keith Flaherty, 2 Richard Kefford, 3 Paolo A. Ascierto, 4 Laure Moutouh-de Parseval,
More informationTargeted Therapies 5/21/2018. Iatrogenic Dermatopathology: When Therapy Goes Wrong
Iatrogenic Dermatopathology: When Therapy Goes Wrong Tammie Ferringer, MD Geisinger Medical Center, Danville, PA tferringer@geisinger.edu I do not have any relevant relationships with industry Targeted
More informationAcute drug reactions associated with the novel targeted therapies used in treating skin cancer
Acute drug reactions associated with the novel targeted therapies used in treating skin cancer Dr Rishika Sinha Consultant Dermatologist Chelsea & Westminster Hospital NHS Foundation Trust West Middlesex
More informationLiposomal Doxorubicin (CAELYX) Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Liposomal Doxorubicin (CAELYX) Gynaecological Cancer PROCTOCOL REF: OPHAGYNCAE (Version No: 1.0) Approved for use in: Advanced ovarian cancer second/third line treatment
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: SUNitinib 50mg Therapy INDICATION ICD10 Regimen Code *Reimbursement Status Treatment of unresectable and/or metastatic malignant gastrointestinal C26 00325a CDS stromal tumour (GIST)
More informationEczema & Dermatitis Clinical features: Histopathological features: Classification:
Eczema & Dermatitis Eczema is an inflammatory reactive pattern of skin to many and different stimuli characterized by itching, redness, scaling and clustered papulovesicles. Eczema and dermatitis are synonymous
More informationREGISTRY OF SEVERE CUTANEOUS ADVERSE REACTIONS TO DRUGS AND COLLECTION OF BIOLOGICAL SAMPLES. R e g i S C A R PATIENT'S DATA. Age country of birth
REGISTRY OF SEVERE CUTANEOUS ADVERSE REACTIONS TO DRUGS AND COLLECTION OF BIOLOGICAL SAMPLES R e g i S C A R PATIENT'S DATA Initials of the patient date of birth Age country of birth Gender male female
More informationPrimary Care Management of the Kidney Cancer Patient
Primary Care Management of the Kidney Cancer Patient Elaine Lam, MD Mountain States Cancer Conference 2016 November 5, 2016 Learning Objectives 1. Understand the mechanisms of action of currently approved
More informationConflicts of Interest GI Malignancies: An Update on Current Treatment Options
Conflicts of Interest GI Malignancies: An Update on Current Treatment Options Nothing to disclose Trevor McKibbin, PharmD, MS, BCOP Clinical Specialist, Hematology/Oncology Winship Cancer Institute of
More informationBRAF Inhibition in Melanoma
BRAF Inhibition in Melanoma New York City, Mar 22-23, 2013 Bartosz Chmielowski, MD, PhD Assistant Clinical Professor University of California Los Angeles Disclosures Speaker Bureau: BMS, Genentech, Prometheus
More informationBARCELONA CLINIC LIVER CANCER (BCLC) STAGING AND TREATMENT STRATEGY FOR HEPATOCELLULAR CARCINOMA (HCC) 1
BARCELONA CLINIC LIVER CANCER (BCLC) STAGING AND TREATMENT STRATEGY FOR HEPATOCELLULAR CARCINOMA (HCC) 1 HCC Very early stage () Early stage (A) Intermediate stage (B) Advanced stage (C) Terminal stage
More informationReDOS Trial Background
Regorafenib Dose Optimization Study (ReDos) A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mcrc) Abstract
More informationDiagnosis and Management of Common and Infective Skin Diseases in Children at primary care level
Diagnosis and Management of Common and Infective Skin Diseases in Children at primary care level Dr Ng Su Yuen Paediatrician and Paediatric Dermatologist Hospital Pulau Pinang Outline Common inflammatory
More informationMEK/BRAF inhibitors and the implications on patients and health care providers
MEK/BRAF inhibitors and the implications on patients and health care providers Tara McKeown NP Paediatric Neuro Oncology Hospital for Sick Children Adjunct Lecturer, Lawrence S. Bloomberg, Faculty of Nursing,
More informationOral Systemic Therapy- Adverse Drug Reaction Management Guide
Oral Systemic Therapy- Adverse Drug Reaction Management Guide AXITINIB Most patients treated with Axitinib will experience adverse effects, but the effects will differ from one patient to the next. Symptoms
More informationSkin Deep Into Toxicities of Cancer Therapies. Mario E Lacouture MD Member, Memorial Hospital Director, Oncodermatology Program New York, NY
Skin Deep Into Toxicities of Cancer Therapies Mario E Lacouture MD Member, Memorial Hospital Director, Oncodermatology Program New York, NY Targeting the Immune System in Cancer. Sharma et al, Nat Rev
More informationIntegumentary System
Integumentary System Integumentary System Skin, hair, and nails. Skin: Epidermis: outer layer. Dermis: also called corium, or true skin. Subcutaneous fascia: innermost layer. Integumentary Glands Sudoriferous:
More informationSorafenib Side effects and dose adjustment SORAMIC
Sorafenib Side effects and dose adjustment 1 Adverse events: prevention and management as key Patients should be informed to: Take preventive measures, where possible Be aware and report AEs as soon as
More informationWhat You Need to Know about Advanced Melanoma Therapies Targeted Approaches
2018 AAD Annual Meeting, San Diego, CA What You Need to Know about Advanced Melanoma Therapies Targeted Approaches Susan M. Swetter, MD, FAAD Professor of Dermatology Director, Pigmented Lesion & Melanoma
More information12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval
12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval ARMANDO SANTORO Roma 10-6-2016 SORAFENIB APPROVAL 29 OCTOBER 2007 Marketing authorization
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationSUNitinib 37.5mg Therapy
INDICATIONS FOR USE: SUNitinib 37.5mg Therapy Regimen Code INDICATION ICD10 Treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression
More informationMy Algorithm. Questions to ask. Do you or your family have a history of?... Allergic rhinitis, Sensitive skin, Asthma Skin Cancer
Tracey C. Vlahovic, DPM Associate Professor, Temple University School of Podiatric Medicine My Algorithm Inflammatory Skin Disorder on Feet Family hx, clinical exam, look at hands! Defined plaques: Psoriasis
More informationSorafenib (so-ra-fe-nib) is a drug that is used to treat many types of cancer. It is a tablet that you take by mouth.
For the Patient: Other names: Sorafenib NEXAVAR Sorafenib (so-ra-fe-nib) is a drug that is used to treat many types of cancer. It is a tablet that you take by mouth. A blood test may be taken before each
More informationcontinuing education Prevention and management of hand-foot syndromes Jia Conway, DNP, FNP-BC, NP-C
continuing education educational objectives After participating in this activity, clinicians should be better able to Identify a novel anticancer therapy that contributes to hand-foot syndromes and hand-foot
More informationDrug Allergy A Guide to Diagnosis and Management
Drug Allergy A Guide to Diagnosis and Management (Version 1 April 2015 updated April 2018) Author: Jed Hewitt Chief Pharmacist, Governance & Professional Practice Date of Preparation: April 2015 Updated:
More informationUpdates in the Management of Epidermal Growth Factor Receptor (EGFR) Inhibitors- Induced Skin Rash. Outline. Signal Transduction
Updates in the Management of Epidermal Growth Factor Receptor (EGFR) Inhibitors- Induced Skin Rash Siu-Fun Wong, PharmD, FASHP, FCSHP Associate Professor of Pharmacy Practice Western University of Health
More informationSide effects of Targeted Therapy
Side effects of Targeted Therapy Joanne Bird NIHR Research Fellow Clare Warnock Senior Project Nurse Types of Anti Cancer Therapy Biological Therapies Cytotoxic Drugs (Chemotherapy) Antibiotics Antimetabolites
More information1. Erythema. 2. Edema/papulation. 3. Excoriation 4. Lichenification
How to Use EASI The EASI scoring system uses a defined process to grade the severity of the signs of eczema and the extent affected: 1. Select a body region Four body regions are considered separately:
More informationGROUP 15 TOPICAL PREPARATIONS
- 105 - GROUP 15 15.1 DERMATOLOGICAL PREPARATIONS 15.1.1 TOPICAL ANTIFUNGALS CLOTRIMAZOLE Indication: Treatment of susceptible fungal infections, dermatophytoses, superficial mycoses, and cutaneous candidiasis
More informationDiphencyprone (DCP) treatment
Page 1 of 5 Diphencyprone (DCP) treatment Introduction This leaflet gives you information about Diphencyprone (DCP) treatment for alopecia areata and answers some of the commonly asked questions. What
More informationManaging Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting
Managing Adverse Events in the Cancer Patient Lisa A Thompson, PharmD, BCOP Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Learning Objectives Describe
More informationSkin toxicities from cancer treatments
Outline Skin toxicities from cancer treatments Resident Power Hour Cecilia Larocca, MD Centers for Melanoma and Cutaneous Oncology Brigham and Women s Hospital/Dana- Farber Cancer Institute Harvard Medical
More informationPodiatry in Practice. Alan M. Singer, DPM, FACFAS
Podiatry in Practice Alan M. Singer, DPM, FACFAS Podiatry in Practice Alan Singer, D.P.M. UNIVERSITY PODIATRY GROUP Onychomycosis Anti-fungals Onychocryptosis (Ingrown Nails) Ingrown Nails Partial Nail
More informationCapecitabine Oxaliplatin 21 day cycle (CAPOX)
Systemic Anti Cancer Treatment Protocol Oxaliplatin 21 day cycle (CAPOX) PROTOCOL REF: MPHACAPOX (Version No: 1.0) Approved for use in: Adjuvant colorectal cancer stage 3 or high risk stage 2 Advanced
More informationDOSING AND INFORMATION GUIDE LEAPS AHEAD
DOSING AND INFORMATION GUIDE In patients with WT RAS* mcrc 1 VECTIBIX (panitumumab) LEAPS AHEAD 5.6-month increase in median OS with FOLFOX vs FOLFOX alone 1 Spot the difference. CHOOSE VECTIBIX PRIME
More informationInitial Results from an Open-label, Doseescalation Phase I Study of the Oral BRAF Inhibitor LGX818 in BRAF V600 mutant Advanced Melanoma
Initial Results from an Open-label, Doseescalation Phase I Study of the Oral BRAF Inhibitor LGX818 in BRAF V600 mutant Advanced Melanoma Reinhard Dummer, 1 Caroline Robert, 2 Marta Nyakas, 3 Grant McArthur,
More informationContents. Part I Genodermatoses
Contents Part I Genodermatoses 1 Hyperkeratotic Palms and Soles with Periorificial Keratosis............... 3 2 Indurated, Dark, Hairy Plaques, with Arthritis and Deafness.............. 9 3 Cleft Palate,
More informationClinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma
european urology supplements 7 (2008) 593 600 available at www.sciencedirect.com journal homepage: www.europeanurology.com Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced
More informationOral Systemic Therapy- Adverse Drug Reaction Management Guide DASATINIB
Oral Systemic Therapy- Adverse Drug Reaction Management Guide DASATINIB Most patients treated with Dasatinib will experience adverse effects, but the effects will differ from one patient to the next. Symptoms
More informationMEET ROY*: A PATIENT WITH LIVER-LIMITED mcrc
MEET ROY*: A PATIENT WITH LIVER-LIMITED mcrc * A hypothetical case study of a patient eligible for first-line mcrc therapy. mcrc = metastatic colorectal cancer. WHAT CLINICAL CHARACTERISTICS AFFECT YOUR
More informationNursing s Role in the Management of New Oral Chemotherapy Agents
Nursing s Role in the Management of New Oral Chemotherapy Agents Mechelle Barrick BSN, RN, OCN, CCRP Clinical Research Nurse Coordinator Greater Baltimore Medical Center mbarrick@gbmc.org THE NURSES ROLE
More informationBCCA Protocol Summary for Therapy of Metastatic Breast Cancer using Capecitabine
BCCA Protocol Summary for Therapy of Metastatic Breast Cancer using Capecitabine Protocol Code Tumour Group Contact Physician BRAVCAP Breast Dr. Susan Ellard ELIGIBILITY: First line treatment of metastatic
More informationالاكزيماتيد= Eczematid
1 / 7 2 / 7 Pityriasis Debate confusing of hypopigmentation characterized increasing surrounded differ hypomelanotic "progressive exists alba misnomer extensive a to observed term the applied term derived
More informationSkin Problems. Issues for a Child. Skin Problems. Paediatric Palliative Care For Home Based Carers. Common in children with HIV
Skin Problems Paediatric Palliative Care For Home Based Carers Funded by British High Commission, Pretoria Small Grant Scheme Skin Problems Common in children with HIV Often conditions common in all children
More informationDERMATOLOGICAL EMERGENCIES. DR. Ian Hoyle MBBS DIP IMC RCS (Ed), DA (UK),FRACGP,FACRRM,DIP DERM(Wales) TASMANIAN SKIN AND BODY CENTRE
DERMATOLOGICAL EMERGENCIES DR. Ian Hoyle MBBS DIP IMC RCS (Ed), DA (UK),FRACGP,FACRRM,DIP DERM(Wales) TASMANIAN SKIN AND BODY CENTRE Dermatological Emergencies INFECTIONS ERYTHRODERMA DRUG ERUPTIONS STEVENS-JOHNSON
More informationEmergency Dermatology. Emergency Dermatology
Emergency Dermatology These are rapidly progressive skin conditions and some are potentially lifethreatening. Early recognition is important to implement prompt supportive care and therapy. Some are drug
More informationCarboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Carboplatin / CARBO/CAELYX Gynaecological Cancer PROCTOCOL REF: MPHAGYNCCX (Version No: 1.0) Approved for use in: Advanced ovarian cancer in women who have progressed
More informationBCCA Protocol Summary for Adjuvant Therapy of Colon Cancer using
BCCA Protocol Summary for Adjuvant Therapy of Colon Cancer using Capecitabine Protocol Code Tumour Group Contact Physician GIAJCAP Gastrointestinal GI Systemic Therapy ELIGIBILITY: Resected Stage III or
More informationPazopanib in Renal cell carcinoma
REGIMEN TITLE: Pazopanib in Renal cell carcinoma Page 1 of 5 Indication: Notes: First line treatment option in advanced renal cell carcinoma Patients who have not received prior cytokine therapy Eastern
More informationCutanous Manifestation of Lupus Erythematosus. Presented By: Dr. Naif S. Al Shahrani Salman Bin Abdaziz university
Cutanous Manifestation of Lupus Erythematosus Presented By: Dr. Naif S. Al Shahrani Salman Bin Abdaziz university A 50-year old lady, who is otherwise healthy, presented to the dermatology clinic with
More informationCapecitabine Oxaliplatin 21 day cycle (XELOX)
Systemic Anti Cancer Treatment Protocol Capecitabine Oxaliplatin 21 day cycle (XELOX) PROTOCOL REF: MPHAXELOX (Version No: 1.0) Approved for use in: Adjuvant colorectal cancer stage 3 or high risk stage
More informationRegorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer
News Release Not intended for U.S. and UK Media Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com Regorafenib from Bayer Submitted
More informationOral Chemotherapy Nathan Brashear, PharmD Candidate 2017 University of Kentucky College of Pharmacy
Oral Chemotherapy Nathan Brashear, PharmD Candidate 2017 University of Kentucky College of Pharmacy 1 Objectives Identify the more commonly dispensed oral chemotherapy drugs and their indications/dosage
More informationBCCA Protocol Summary for the Treatment of BRAF V600 Mutation- Positive Unresectable or Metastatic Melanoma using vemurafenib and cobimetinib
BCCA Protocol Summary for the Treatment of BRAF V600 Mutation- Positive Unresectable or Metastatic Melanoma using vemurafenib and cobimetinib Protocol Code Tumour Group Contact Physician USMAVVC Skin and
More informationBCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Capecitabine and Radiation Therapy
BCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, and Radiation Therapy Protocol Code: Tumour Group: Contact Physician: GICART Gastrointestinal
More informationThe EASI scoring system uses a defined process to grade the severity of the signs of eczema and the extent affected:
How to Use EASI The EASI scoring system uses a defined process to grade the severity of the signs of eczema and the extent affected: 1. Select a body region Four body regions are considered separately:
More informationKidney Cancer. Version February 6, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines )
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Kidney Cancer Overall management of Kidney Cancer from diagnosis through recurrence is described in the full NCCN Guidelines for Kidney
More informationDiabetes - Foot Care
Diabetes - Foot Care Introduction People with diabetes are more likely than others to have problems with their feet. These problems can lead to dangerous infections of the foot. Recognizing and treating
More informationeczema the basics 2EE6E629CEA25112ABD0B8EB Eczema The Basics 1 / 6
Eczema The Basics 1 / 6 2 / 6 3 / 6 Eczema The Basics Eczema is a group of conditions that cause inflammation of the skin. Typically, eczema causes skin to become itchy, red, and dry -- even cracked and
More informationErdheim-Chester disease and Skin issues
Erdheim-Chester disease and Skin issues STÉPHANE BARETE, MD, PHD UNIT OF DERMATOLOGY PITIÉ -SALPÊTRIÈRE HOSPITAL PARIS stephane.barete@aphp.fr Introduction Erdheim-Chester (ECD) is an orphan disease included
More informationSkin lesions & Abrasions
Skin lesions & Abrasions What Are Skin Lesions? A skin lesion is a part of the skin that has an abnormal growth or appearance compared to the skin around it Types of Skin Lesions Two types of skin lesions
More informationRecalcitrant Warty Erythroderma With Severe Pruritus. Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University
Recalcitrant Warty Erythroderma With Severe Pruritus Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY Gil Yosipovitch,
More informationTexas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD)
Diagnosis: ATOPIC DERMATITIS (AD) Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD) PATIENT ADVICE: Unfortunately, there is no cure for atopic dermatitis, so
More informationProspective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib
670368CMSXXX10.1177/1203475416670368Journal of Cutaneous Medicine and SurgeryLacroix and Wang research-article2016 Original Article Prospective Case Series of Cutaneous Adverse Effects Associated With
More informationFor the Patient: Sunitinib Other names: SUTENT
For the Patient: Sunitinib Other names: SUTENT Sunitinib (soo-ni-ti-nib) is a drug that is used to treat different types of cancer. It is a capsule that you take by mouth. A blood test and blood pressure
More informationLung Pathway Group Afatinib in Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Afatinib in Non-Small Cell Lung Cancer (NSCLC) Indication: NICE TA310 First line treatment option in locally advanced or metastatic NSCLC Positive test for epidermal growth factor receptor
More informationTAO-Cancer Toxicity Management: Cutaneous Toxicities of Immunotherapies
TAO-Cancer Toxicity Management: Cutaneous Toxicities of Immunotherapies Mario E Lacouture MD Director, Oncodermatology Program Attending, Dermatology www. MSKCC.org Dermatologic Care With Immunotherapies
More informationFor the Patient: USMAVTRA Other Names: Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using Trametinib
For the Patient: USMAVTRA Other Names: Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using Trametinib SM = Skin and Melanoma AV = AdVanced TRA = Trametinib ABOUT THIS MEDICATION
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/35807 holds various files of this Leiden University dissertation. Author: Wit, Djoeke de Title: Dose optimization of oral targeted therapies in oncology
More informationBMT CTN 0801 Protocol. Chronic GVHD Provider Survey ENROLLMENT
BMT CTN 0801 Protocol Chronic GVHD Provider Survey ENROLLMENT Instructions: Please score a symptom only if you know or suspect it be related to chronic GVHD. Subjective are acceptable. For example, joint
More informationHerceptin (Trastuzumab) plus Capecitabine & Cisplatin (HCX)
Herceptin (Trastuzumab) plus Capecitabine & Cisplatin (HCX) DRUG ADMINISTRATION SCHEDULE First Cycle Only: Day Drug Daily Dose Route Diluent and Rate 1 to 21 Capecitabine 625mg/m 2 Day 1 TWICE DAILY Oral
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationBMT CTN 0801 Protocol. Chronic GVHD Provider Survey. FOLLOW-UP v3.0
BMT CTN 0801 Protocol Chronic GVHD Provider Survey FOLLOW-UP v3.0 Instructions: Please score a symptom only if you know or suspect it be related to chronic GVHD. Subjective are acceptable. For example,
More informationBCCA Protocol Summary for Second line Treatment of Metastatic or Unresectable Pancreatic Adenocarcinoma Using Capecitabine
BCCA Protocol Summary for Second line Treatment of Metastatic or Unresectable Pancreatic Adenocarcinoma Using Capecitabine Protocol Code Tumour Group Contact Physician GIPAVCAP Gastrointestinal GI Systemic
More informationICHTHYOSIS. What are the aims of this leaflet?
ICHTHYOSIS What are the aims of this leaflet? This leaflet has been written to help you understand more about ichthyosis. It will tell you what it is, the types of ichthyosis, what can be done about it,
More informationATOPIC ECZEMA. What are the aims of this leaflet?
ATOPIC ECZEMA What are the aims of this leaflet? This leaflet has been written to help you understand more about atopic eczema. It tells you what it is, what causes it, what can be done about it, and where
More information2) Disorders of Abnormal Keratinization - Dr. Ali
2) Disorders of Abnormal Keratinization - Dr. Ali Disorder of Keratinization In the normal epidermis, as the keratinocytes move from the basal-cell layer to the surface, the process of terminal differentiation
More informationVulval dermatoses. Dr Fiona Lewis, Consultant Dermatologist St John s Institute of Dermatology, London & Heatherwood & Wexham Park Hospital, Slough
Vulval dermatoses Dr Fiona Lewis, Consultant Dermatologist St John s Institute of Dermatology, London & Heatherwood & Wexham Park Hospital, Slough Pigmentation Vulvodynia Ulcers Genetic Pruritus VULVAL
More informationBreast Pathway Group Docetaxel in Advanced Breast Cancer
Breast Pathway Group Docetaxel in Advanced Breast Cancer Indication: First-line palliative treatment, with or without trastuzumab, for advanced breast cancer in patients for whom an anthracycline is not
More informationDermclinic
Dermclinic /Dermclinic A Photo Quiz to Hone Dermatologic Skills DAVID L. KAPLAN, MD Series Editor University of Missouri Kansas City, University of Kansas Case 1: Upon his return from a summer visit to
More informationOncology and surgery Yolanda Gilaberte. Hospital Universitario Miguel Servet, Zaragoza
Oncology and surgery Yolanda Gilaberte. Hospital Universitario Miguel Servet, Zaragoza Dermatologic adverse events of oncologic drugs Grading of Dermatologic Adverse Events (ver 5.0) 5 grades: mild, moderate,
More informationREGORAFENIB IN METASTATIC COLORECTAL CANCER AND ADVANCED SOFT TISSUE SARCOMAS
REGORAFENIB IN METASTATIC COLORECTAL CANCER AND ADVANCED SOFT TISSUE SARCOMAS Summary of Presentations from the 2016 Meeting of The American Society of Clinical Oncology (ASCO) held in Chicago, Illinois,
More informationSupplementary Online Content
Supplementary Online Content Foley P, Gordon K, Griffiths, CEM, et al. Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized
More informationPREMEDICATIONS: Antiemetic protocol for highly emetogenic chemotherapy. May not need any antiemetic with
BCCA Protocol Summary for Palliative Therapy of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, or Anal Squamous Cell Carcinoma using
More informationPaediatric Eczema. Dr Manjeet Joshi Consultant Dermatologist 16 th May 2012
Paediatric Eczema Dr Manjeet Joshi Consultant Dermatologist 16 th May 2012 Classification of the principal forms of eczema EXOGENOUS ENDOGENOUS Irritant Allergic contact Photoallergic contact Eczematous
More informationYour guide to. A non-surgical treatment for Dupuytren's contracture 1 * Patient information
A non-surgical treatment for Dupuytren's contracture 1 * Your guide to The information in this guide is for educational purposes only and is not intended as a substitute for professional medical advice,
More informationIntegumentary System (Skin) Unit 6.3 (6 th Edition) Chapter 7.3 (7 th Edition)
Integumentary System (Skin) Unit 6.3 (6 th Edition) Chapter 7.3 (7 th Edition) 1 Learning Objectives Identify the major components (anatomy) of skin Differentiate between the two types of skin glands Explain
More informationSkin cancer is the most common
Section Editors: Christopher J. Campen and Beth Eaby-Sandy Vemurafenib: First-in-Class BRAF- Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma LINDSAY SHELLEDY, PharmD, and DANIELLE
More informationYour Guide. A resource to provide you with information about your therapy
Your Guide to A resource to provide you with information about your therapy Please see Important Safety Information on pages 4 through 6 and accompanying full Prescribing Information. Pictures are for
More information